Illumina, Inc. ILMN
270.00
(3.90)
(1.42%)
as of 25 Sep
- Market cap
- $41.3B
- P/E
- 50.4×
Follow ILMN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Illumina, Inc. (ILMN) EBITDA
Illumina, Inc.'s EBITDA for fiscal 2025 was $1.1B, compared with −$479.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from −$3.8B (fiscal 2022) to $1.2B (fiscal 2019); the current reading is higher than 82% of that period. EBITDA has risen for 3 consecutive fiscal years. Illumina, Inc. ranks 9th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.1B | — |
| FY2024 | −$479.0M | — |
| FY2023 | −$637.0M | — |
| FY2022 | −$3.8B | — |
| FY2021 | $160.0M | (80.17%) |
| FY2020 | $807.0M | (33.80%) |
| FY2019 | $1.2B | 10.52% |
| FY2018 | $1.1B | 39.27% |
| FY2017 | $792.0M | 4.49% |
| FY2016 | $758.0M | (2.70%) |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $315.0M | 13.31% |
| Mar 2026 | $278.0M | 3.73% |
| Dec 2025 | $268.0M | (8.84%) |
| Sep 2025 | $294.0M | 4.26% |
| 42 more quarters | Free account |
Against its own ten years
Low −$3.8B
High $1.2B
Ten-year median
$779.0M
Current reading's percentile
82
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ILMN
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement